Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Methylation discriminators in NSCLC identified by a microarray based approach.

J K Field1, T Liloglou, S Warrak

  • 1Roy Castle Lung Cancer Research Programme, The University of Liverpool Cancer Research Centre, UK. j.k.field@liv.ac.uk

International Journal of Oncology
|June 9, 2005
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Real-world 5-year outcomes with durvalumab after chemoradiotherapy in unresectable stage III NSCLC.

ESMO open·2026
Same author

Real-world outcomes with durvalumab after chemoradiotherapy in patients with unresectable stage III NSCLC: interim analysis of overall survival from PACIFIC-R.

ESMO open·2024
Same author

Large cell neuroendocrine carcinoma of the floor of mouth and retromolar trigone in association with basaloid squamous cell carcinoma.

International journal of oral and maxillofacial surgery·2022
Same author

[Extranodal manifestation of classical Hodgkin lymphoma in the head and neck region].

HNO·2019
Same author

Impact of choice of volumetry software and nodule management guidelines on recall rates in lung cancer screening.

European journal of radiology·2019
Same author

Integrative and comparative genomic analyses identify clinically relevant pulmonary carcinoid groups and unveil the supra-carcinoids.

Nature communications·2019

Aberrant DNA methylation differs between lung cancer subtypes and normal tissue. Specific gene methylation profiles can distinguish squamous cell carcinoma and adenocarcinoma from normal lung tissue.

Area of Science:

  • Oncology
  • Molecular Biology
  • Genetics

Background:

  • Aberrant DNA methylation is common in non-small cell lung cancers (NSCLCs).
  • Understanding methylation differences between NSCLC subtypes and normal tissue is crucial for diagnosis and treatment.
  • Smokers are at higher risk for lung cancer, making this study population relevant.

Purpose of the Study:

  • To identify genes with distinct DNA methylation status differences between squamous cell carcinoma, adenocarcinoma, and normal lung tissue.
  • To explore the potential of DNA methylation profiles for differentiating lung cancer histological types from normal tissue.

Main Methods:

  • A microarray approach was used to analyze DNA methylation status at 245 CpG positions across 59 candidate genes.
  • 26 squamous cell carcinomas, 22 adenocarcinomas, and 26 normal adjacent lung tissues from smokers were analyzed.

Related Experiment Videos

  • Multivariate tests and corrected p-values were employed to identify differentially methylated genes.

    • Main Results:

    • Differential DNA methylation was observed in squamous cell carcinoma compared to normal tissue for ARHI, MGMT, GP1bbeta, RARbeta, and TMEFF2 genes.
    • TMEFF2, MGMT, and CDKN1C genes showed distinct methylation differences between adenocarcinoma and normal tissue.
    • Some identified genes had not been previously associated with lung cancer.

    Conclusions:

    • DNA methylation profiles of specific genes can distinguish between different histological types of lung cancer and normal lung tissue.
    • These findings suggest potential utility of DNA methylation markers for classifying NSCLC subtypes.
    • Further research into the role of novel methylated genes in lung cancer pathogenesis is warranted.